Article

FDA approves treatment for cystinosis

The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
© 2025 MJH Life Sciences

All rights reserved.